Enanta Pharmaceuticals, Inc. (ENTA)
11.34
+0.27
(+2.44%)
USD |
NASDAQ |
Jun 09, 16:00
11.34
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals SG&A Expense (Quarterly) : 9.568M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Arcturus Therapeutics Holdings, Inc. | 9.465M |
| MeiraGTx Holdings Plc | 8.928M |
| Keros Therapeutics, Inc. | 10.15M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |
| Alnylam Pharmaceuticals, Inc. | 322.55M |